ASH 2019 Sanofi's sutimlimab delivers benefit for CAD patients in phase III study Dec. 10, 2019 By Michael Fitzhugh No Comments ORLANDO, Fla. – New research on sutimlimab, an investigational complement pathway inhibitor under development by Sanofi SA's Bioverativ unit, showed substantial benefits for people with the rare autoimmune disorder cold agglutinin disease (CAD).Read More